US Patent Issued to ARCUTIS BIOTHERAPEUTICS on May 27 for "Topical roflumilast formulation having improved delivery and plasma half-life" (Colorado Inventor)

ALEXANDRIA, Va., June 17 -- United States Patent no. 12,310,956, issued on May 27, was assigned to ARCUTIS BIOTHERAPEUTICS Inc. (Westlake Village, Calif.).

"Topical roflumilast formulation having improved delivery and plasma half-life" was invented by David W. Osborne (Fort Collins, Colo.).

According to the abstract* released by the U.S. Patent & Trademark Office: "The present invention is directed to methods for improving the therapeutic outcome of treatment with roflumilast. The therapeutic outcome is improved by consistent delivery and/or a longer plasma half-life of a topically administered roflumilast composition. The roflumilast composition preferably includes dicetyl phosphate, ceteth-10 phosphate, diethylene glycol I monoethyl eth...